- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.03. | CalciMedica: NASDAQ bemängelt Börsenwert und Aktienkurs - Delisting droht | 2 | Investing.com Deutsch | ||
| 18.03. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.03. | CalciMedica, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 03.03. | CalciMedica GAAP EPS of -$1.97 | 1 | Seeking Alpha | ||
| CALCIMEDICA Aktie jetzt für 0€ handeln | |||||
| 03.03. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.03. | CalciMedica, Inc.: CalciMedica Reports 2025 Financial Results and Provides Clinical Updates | 726 | PR Newswire | Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related... ► Artikel lesen | |
| 30.01. | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CalciMedica Halts KOURAGE | 909 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic... ► Artikel lesen | |
| 29.01. | This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday | 16 | Benzinga.com | ||
| 28.01. | CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis | 10 | Benzinga.com | ||
| 28.01. | CalciMedica stock craters as calcium channel inhibitor trial stopped over 'safety concern' | 1 | FierceBiotech | ||
| 28.01. | CalciMedica-Aktie bricht nach Studienabbruch zu Nierenversagen um 80 % ein | 8 | Investing.com Deutsch | ||
| 28.01. | CalciMedica discontinues AKI trial following safety concerns | 1 | Investing.com | ||
| 28.01. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.01. | CalciMedica, Inc.: CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation | 747 | PR Newswire | Safety concern warrants reevaluation of study design, including enrollment criteria
Potential future trial with Auxora in AKI to be evaluated after data analysis
... ► Artikel lesen | |
| 02.12.25 | Oppenheimer reiterates Outperform rating on CalciMedica stock ahead of key trial | 4 | Investing.com | ||
| 12.11.25 | CalciMedica, Inc.: CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates | 430 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026
Positive discussions with... ► Artikel lesen | |
| 06.11.25 | CalciMedica, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.10.25 | CalciMedica, Inc.: CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora | 248 | PR Newswire | AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials
LA JOLLA... ► Artikel lesen | |
| 12.08.25 | CalciMedica, Inc.: CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates | 253 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with respiratory failure; data expected in early 2026
Productive initial meeting... ► Artikel lesen | |
| 14.05.25 | CalciMedica, Inc.: CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates | 235 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025
Presentations at... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,15 | +0,22 % | Durchbruch in der Psychotherapie: Emyria meldet 50% Remission - Ein neuer "BioNTech-Moment" für die Mental-Health-Branche? | ||
| MODERNA | 43,480 | +0,49 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| AMGEN | 295,40 | +0,44 % | Amgen Announces Retirement Of David M. Reese, Executive Vice President And Chief Technology Officer | Organizational Changes Further Emphasize Integration of Biology and Technology
THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced... ► Artikel lesen | |
| NOVAVAX | 6,960 | -0,85 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| STRYKER | 280,10 | +0,21 % | Following Stryker Cyberattack, Avatier Launches Identity Challenge Card to Protect Organizations When Standard Security Fails | New Solution Delivers the First Auto-Enrolled, Air-Gapped Multi-Factor Authentication (MFA) That Can Be Deployed Enterprise-Wide in a Single Day: No Devices, Apps, or Network Connectivity RequiredPLEASANTON... ► Artikel lesen | |
| BIOGEN | 156,62 | -0,43 % | Biogen To Acquire TJ Bio's Rights To Felzartamab In The Greater China Region | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater... ► Artikel lesen | |
| ILLUMINA | 109,30 | +0,15 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,050 | +0,18 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,508 | -0,45 % | Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors | BERKELEY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber (the "Company" or "Quantum Cyber"), today announced a strategic update in response... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,660 | +0,17 % | Intellia to report Phase 3 CRISPR gene editing trial results Monday | ||
| TEMPUS AI | 44,665 | +0,42 % | Tempus AI Nears Profitability as Operating Leverage Emerges | ||
| BIOCRYST PHARMACEUTICALS | 7,620 | -0,18 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,390 | +0,04 % | BioMarin Appoints Ian Clark As Board Chair | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN), on Tuesday, announced the appointment of Ian Clark as Chair of the Board, subject to his election at the company's Annual Meeting... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,280 | -0,23 % | Mesoblast: Neue Fantasie durch Technologie - und ein wachsender Zielmarkt | ||
| EXELIXIS | 37,955 | -1,04 % | RBC Capital reiterates Exelixis stock rating on competitive position |
CALCIMEDICA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,591 Euro und damit +0,20 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALCIMEDICA INC finden Sie auf Wallstreet Online.